Trial · NCT04612790
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Responders at Week 36 | DB Period: Benralizumab | 11.1 | 95% Confidence Interval -2.70 to 26.11 | Percentage of participants | |
| Percentage of Responders at Week 36 | DB Period: Placebo | 5.26 | 95% Confidence Interval -5.06 to 15.07 | Percentage of participants | |
| Percentage of Participants Who Remained Relapse-Free up to Week 36 | DB Period: Benralizumab | 23.78 | 95% Confidence Interval 5.95 to 41.61 | Percentage of participants | |
| Percentage of Participants Who Remained Relapse-Free up to Week 36 | DB Period: Placebo | 19.79 | 95% Confidence Interval 1.43 to 38.15 | Percentage of participants | |
| Cumulative OCS Exposure From Baseline to Week 36 | DB Period: Benralizumab | 71.37 | Standard Deviation 63.19 | mg per kilogram (mg/kg) | |
| Cumulative OCS Exposure From Baseline to Week 36 | DB Period: Placebo | 62.71 | Standard Deviation 46.90 | mg per kilogram (mg/kg) | |
| Change From Baseline in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score at Week 36 | DB Period: Benralizumab | -53.29 | Standard Deviation 46.33 | Score on a scale | |
| Change From Baseline in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score at Week 36 | DB Period: Placebo | -52.75 | Standard Deviation 17.36 | Score on a scale | |
| Change From Baseline in BPDAI-Pruritus Score at Week 36 | DB Period: Benralizumab | -5.57 | Standard Deviation 7.23 | Score on a scale | |
| Change From Baseline in BPDAI-Pruritus Score at Week 36 | DB Period: Placebo | -16.58 | Standard Deviation 9.21 | Score on a scale | |
| Cumulative OCS Exposure From Baseline to Week 16 | DB Period: Benralizumab | 46.90 | Standard Deviation 27.19 | mg/kg | |
| Cumulative OCS Exposure From Baseline to Week 16 | DB Period: Placebo | 42.15 | Standard Deviation 33.33 | mg/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04612790/results